KMT2A and leukemia: Recently, many small molecule PPI inhibitors, such as MLL1-menin and MLL1-WDR5 interaction inhibitors, were synthesized and entered into clinical trials for AML, suggesting that PPIs involving DOT1L may have similar potential for MLL-rearranged leukemias.